品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
罗恩 | R028440-10mg | 10mg | 5~7个工作日 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
罗恩 | R028440-50mg | 50mg | 5~7个工作日 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
罗恩 | R028440-5mg | 5mg | 5~7个工作日 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
罗恩 | R028440-1mg | 1mg | 5~7个工作日 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
阿拉丁 | S126833-5mg | 5mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S126833-10mg | 10mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S126833-50mg | 50mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S126833-1mg | 1mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S126833-25mg | 25mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S126833-100mg | 100mg | 现货 | 501951-42-4 |
SB705498,hTRPV1拮抗剂 SB705498 |
Moligand™, ≥98% |
|
|
阿拉丁 | S408877-1ml | 1ml | 现货 | 501951-42-4 |
SB705498 SB705498 |
Moligand™, 10mM in DMSO |
|
|
韶远 | SY097699-1g | 1g | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-[1-[5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-[1-[... |
≥95% |
|
|
毕得 | BD300171-50mg | 50mg | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-(1-(5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-(1-(... |
99% |
|
|
毕得 | BD300171-100mg | 100mg | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-(1-(5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-(1-(... |
99% |
|
|
毕得 | BD300171-10mg | 10mg | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-(1-(5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-(1-(... |
99% |
|
|
毕得 | BD300171-250mg | 250mg | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-(1-(5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-(1-(... |
99% |
|
|
毕得 | BD300171-1g | 1g | 现货 | 501951-42-4 |
(R)-1-(2-溴苯基)-3-(1-(5-(三氟甲基)... (R)-1-(2-Bromophenyl)-3-(1-(... |
99% |
|
|
源叶 | S80751-5mg | 5mg | 现货 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
源叶 | S80751-10mg | 10mg | 现货 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|
源叶 | S80751-50mg | 50mg | 现货 | 501951-42-4 |
SB705498 SB705498 |
99% |
|
|